The majority of the secondary objectives, including protection against gastro-intestinal damage (when ulcers and erosions are combined), were achieved and overall AZD3582 was well tolerated.

AstraZeneca remains committed to the completion of the ongoing AZD3582 Phase II development programme.

AstraZeneca, together with NicOx, will review the data generated from the several ongoing AZD3582 Phase II clinical studies in the programme in order to decide on the further development plans for AZD3582 and the CINOD class.